Supplementary Figure S3 from the ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Nicole R. Infarinato,Jin H. Park,Kateryna Krytska,Hannah T. Ryles,Renata Sano,Katherine M. Szigety,Yimei Li,Helen Y. Zou,Nathan V. Lee,Tod Smeal,Mark A. Lemmon,Yael P. Mossé

crossref（2023）

引用 0|浏览0

暂无评分

摘要

In vivo efficacy studies comparing PF-06463922 treatment at 10 mg/kg/day (5 mg/kg BID) and 3 mg/kg/day (1.5 mg/kg BID) with crizotinib treatment at 100 mg/kg QD in: A, Felix-PDX xenografts and B, SH-SY5Y xenografts.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要